The 4th floor of the new South Pavilion at Duke Raleigh Hospital will be utilized primarily for surgical oncology inpatients.
Grand Opening: Duke Raleigh Hospital Expands with "South Pavilion"
Published
From the Duke Cancer Institute archives. Content may be out of date.
Duke Raleigh Hospital has announced the completion of its South Pavilion, an extension of the existing hospital (the North Pavilion). The multi-million dollar project allows Duke Raleigh Hospital to make the necessary advancements for its patients, their loved ones, and each other as the community grows and its health needs evolve. When the more than 210,000 square foot South Pavilion opens to its first inpatients on July 12, it will include:
92 private inpatient rooms, including 28 ICU and 64 acute care
9 state of the art operating rooms with an expanded sterile processing department
Family Waiting Areas overlooking Wake Forest Road on each inpatient floor.
An outdoor courtyard with dining areas and a walking path that connects to the Surgical Services waiting area and the new cafe.
A new kitchen and cafe offering a variety of culinary flavors and seating for close to 200 guests
Artwork by regional artists
“The newly completed South Pavilion has added space, not just for innovative care, but more room for families to be involved in the process of care during their stay here,” said Leigh Bleecker, interim president, Duke Raleigh Hospital. “The modern, welcoming look of the South Pavilion was a key part of the design. The building really allows Duke Raleigh Hospital to create a healing space for our community that embraces all the ways in which our mind, body, and spirit can be restored.”
Duke Raleigh Hospital will host a virtual grand opening ceremony for the new "South Pavilion" from 1 to 1:30 p.m. on Thursday, July 8. All members of the community are invited to join the ceremony.
A Duke-led study published in iScience provides new insights into the tumor microenvironment of brain metastases, identifying distinct macrophage populations associated with patient survival and highlighting potential targets for future therapeutic intervention.Brain metastases remain a significant clinical challenge across multiple tumor types, including breast cancer, lung cancer, and melanoma. Despite advances in systemic therapies and local treatment approaches, outcomes remain poor for many patients, underscoring the need for a deeper understanding of the biological mechanisms driving disease progression.Using an integrated multi-omic approach, investigators analyzed 23 human brain metastasis specimens through single-nucleus RNA sequencing and spatial transcriptomic profiling. The study leveraged these complementary technologies to characterize cellular heterogeneity within the tumor microenvironment and define spatial relationships between immune and tumor cell populations.The analysis revealed substantial macrophage heterogeneity and demonstrated that macrophage-associated transcriptional programs differ significantly between patients with favorable and unfavorable survival outcomes. Specifically, inflammatory macrophage populations localized at the tumor boundary were associated with improved survival, while macrophage populations characterized by extracellular matrix remodeling signatures and TGFβ1 expression were associated with poorer outcomes.These findings suggest that distinct macrophage subtypes may play context-dependent roles in brain metastatic progression, functioning as either tumor-restrictive or tumor-supportive components of the microenvironment. The results further emphasize the importance of spatial cellular organization in shaping disease biology and clinical outcomes.Importantly, the study extends current understanding of immune-tumor interactions in brain metastases by linking specific macrophage subtypes and locations within the tumor ecosystem to survival-associated phenotypes. The identification of these distinct cellular programs may provide a framework for the development of novel therapeutic strategies aimed at modulating macrophage function or disrupting protumor signaling networks within the metastatic niche.As the incidence of brain metastases continues to increase and therapeutic resistance remains a critical barrier to long-term disease control, these findings represent an important step toward the development of more precise, microenvironment-directed treatment approaches. Further investigation will be needed to validate these observations and assess their translational potential in prospective clinical studies.This work was a joint research collaboration among Duke Center for Brain and Spine Metastasis (DCBSM) members: Dr. Ann Marie Pendergast (Department of Pharmacology and Cancer Biology, Duke University School of Medicine), Dr. Carey Anders (Department of Medicine, Division of Medical Oncology), and Dr. Simon Gregory (Department of Neurosurgery, and Duke Molecular Physiology Institute), and first-author Dr. Aaditya Khatri (Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Duke University School of Medicine).
A Duke-led study published in iScience provides new insights into the tumor microenvironment of brain metastases, identifying distinct macrophage populations associated with patient survival and highlighting potential targets for future therapeutic intervention.Brain metastases remain a significant clinical challenge across multiple tumor types, including breast cancer, lung cancer, and melanoma. Despite advances in systemic therapies and local treatment approaches, outcomes remain poor for many patients, underscoring the need for a deeper understanding of the biological mechanisms driving disease progression.Using an integrated multi-omic approach, investigators analyzed 23 human brain metastasis specimens through single-nucleus RNA sequencing and spatial transcriptomic profiling. The study leveraged these complementary technologies to characterize cellular heterogeneity within the tumor microenvironment and define spatial relationships between immune and tumor cell populations.The analysis revealed substantial macrophage heterogeneity and demonstrated that macrophage-associated transcriptional programs differ significantly between patients with favorable and unfavorable survival outcomes. Specifically, inflammatory macrophage populations localized at the tumor boundary were associated with improved survival, while macrophage populations characterized by extracellular matrix remodeling signatures and TGFβ1 expression were associated with poorer outcomes.These findings suggest that distinct macrophage subtypes may play context-dependent roles in brain metastatic progression, functioning as either tumor-restrictive or tumor-supportive components of the microenvironment. The results further emphasize the importance of spatial cellular organization in shaping disease biology and clinical outcomes.Importantly, the study extends current understanding of immune-tumor interactions in brain metastases by linking specific macrophage subtypes and locations within the tumor ecosystem to survival-associated phenotypes. The identification of these distinct cellular programs may provide a framework for the development of novel therapeutic strategies aimed at modulating macrophage function or disrupting protumor signaling networks within the metastatic niche.As the incidence of brain metastases continues to increase and therapeutic resistance remains a critical barrier to long-term disease control, these findings represent an important step toward the development of more precise, microenvironment-directed treatment approaches. Further investigation will be needed to validate these observations and assess their translational potential in prospective clinical studies.This work was a joint research collaboration among Duke Center for Brain and Spine Metastasis (DCBSM) members: Dr. Ann Marie Pendergast (Department of Pharmacology and Cancer Biology, Duke University School of Medicine), Dr. Carey Anders (Department of Medicine, Division of Medical Oncology), and Dr. Simon Gregory (Department of Neurosurgery, and Duke Molecular Physiology Institute), and first-author Dr. Aaditya Khatri (Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Duke University School of Medicine).
